Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05656469 · ClinicalTrials.gov registry record · NA
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
A NA study of Anxiety Disorders and Mood Disorders, sponsored by Maastricht University Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 2,500
- Enrollment target
- 9
- Study locations
NCT05656469 is a NA study of Anxiety Disorders and Mood Disorders that is actively recruiting participants, run by Maastricht University Medical Center. The registered enrollment target is 2,500 participants, above the 1,110-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (125% higher). The trial reports 9 study locations across 2 states.
The verdict
NCT05656469, a NA study of Anxiety Disorders and Mood Disorders, is actively recruiting participants, sponsored by Maastricht University Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,500 participants
- Enrollment target
- 9
- Study locations
Study Summary
A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.
Conditions Studied
Interventions
- OTHER Personalised medication advice based on pharmacogenetic testing
Study Locations (9)
Other
- University Hospital Bonn, Department of Psychiatry and Psychotherapy - Bonn
- Ludwig-Maximilian University, University Hospital, Institute of Psychiatric Phenomics and Genomics (IPPG) - München
- Parnassia Psychiatric Institute, Department of Psychiatry - Amsterdam
- Maastricht University, Department of Psychiatry and Neuropsychology - Maastricht
- Babeş-Bolyai University, Department of Clinical Psychology and Psychotherapy - Cluj-Napoca
- University of Belgrade, Faculty of Pharmacy - Belgrade
- Fundació Clínic per a la Recerca Biomèdica, Department of Psychiatry and Psychology, Hospital Clínic - Barcelona
- King's College, Institute of Psychiatry, Psychology & Neuroscience - London
New York
- SUNY Upstate Medical University, Department of Psychiatry and Behavioural Sciences - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2023-02-23 |
| Est. Completion | 2026-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05656469
The ClinicalTrials.gov registry entry for NCT05656469 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,110-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (125% higher). The listed sponsor is Maastricht University Medical Center, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Anxiety Disorders appearing as the primary indexed condition, and to 1 intervention - of which Personalised medication advice based on pharmacogenetic testing is the first listed.
NCT05656469 reports 9 study locations spanning 2 distinct geographic areas - top geographies include Other, New York.
Frequently Asked Questions
What is clinical trial NCT05656469 about?
NCT05656469 is a clinical study titled "Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders". A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders...
What is the current status of trial NCT05656469?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,500 participants. The study started on 2023-02-23. Estimated completion is 2026-09.
What conditions does trial NCT05656469 study?
This clinical trial studies the following conditions: Anxiety Disorders, Mood Disorders, Psychotic Disorders.
What interventions are being tested in trial NCT05656469?
The interventions under investigation include: Personalised medication advice based on pharmacogenetic testing (OTHER).
Who is sponsoring clinical trial NCT05656469?
This trial is sponsored by Maastricht University Medical Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05656469 being conducted?
This trial has 9 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
-
CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos
RECRUITING · NA
-
Initial Assessment of the Feasibility and Efficacy of a Scalable Digital CBT for Generalized Anxiety and Associated Health Behaviors in a Cardiovascular Disease Population
RECRUITING · NA
-
Managing Anxiety in Pediatric Primary Care (MAPP)
RECRUITING · NA
-
DINO RCT - Treating Anxiety in Children With Autism
RECRUITING · NA
-
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.